GSK plc (GLAXF) stock
GLAXFOTCPharmaceutical PreparationsAlso trades as GSK
Financials through fiscal 2025, year ended Dec 31, 2025Score 9/30
$24.74+0.30 (+1.21%)
Close on Oct 19, 2026Market cap $106.83BP/E 13.3Yield –
GSK cash
Cash and short-term investments held at the end of each period.
GSK's cash was £3.40B at Dec 31, 2025. For fiscal 2025 it was £3.40B, down 12.2% from the year before. Over ten years it grew -5.3% a year on average. The highest annual figure on record is £6.29B in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | £3.40B | -12.2% |
| FY2024 | Dec 31, 2024 | £3.87B | +31.8% |
| FY2023 | Dec 31, 2023 | £2.94B | -21.1% |
| FY2022 | Dec 31, 2022 | £3.72B | -12.9% |
| FY2021 | Dec 31, 2021 | £4.27B | -32.1% |
| FY2020 | Dec 31, 2020 | £6.29B | +33.7% |
| FY2019 | Dec 31, 2019 | £4.71B | +21.5% |
| FY2018 | Dec 31, 2018 | £3.87B | +1.1% |
| FY2017 | Dec 31, 2017 | £3.83B | -21.7% |
| FY2016 | Dec 31, 2016 | £4.90B | -16.0% |
| FY2015 | Dec 31, 2015 | £5.83B | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | £3.40B | -20.5% |
| Q4 FY2024 | Dec 31, 2024 | £3.87B | -38.5% |
| Q4 FY2023 | Dec 31, 2023 | £2.94B | -37.6% |
| Q4 FY2022 | Dec 31, 2022 | £3.72B | -3.9% |
| Q4 FY2021 | Dec 31, 2021 | £4.27B | +11.5% |
| Q4 FY2020 | Dec 31, 2020 | £6.29B | +28.5% |
| Q4 FY2019 | Dec 31, 2019 | £4.71B | -19.3% |
| Q4 FY2018 | Dec 31, 2018 | £3.87B | – |
| Q4 FY2017 | Dec 31, 2017 | £3.83B | – |
| Q4 FY2016 | Dec 31, 2016 | £4.90B | – |
| Q4 FY2015 | Dec 31, 2015 | £5.83B | – |